22-Dec-2025
SCYNEXIS granted Nasdaq extension to regain bid price compliance
Seeking Alpha News (Mon, 22-Dec 9:02 AM ET)
SCYNEXIS Halts Phase 3 MARIO Trial, Raising New Questions for Ibrexafungerp’s Growth Path
TipRanks (Fri, 19-Dec 11:30 AM ET)
SCYNEXIS Completes BREXAFEMME NDA Transfer to GSK—Milestone Payments Could Reach $145.5 Million
Market Chameleon (Thu, 20-Nov 6:45 AM ET)
SCYNEXIS Completes Transfer of BREXAFEMME New Drug Application to GSK
Globe Newswire (Wed, 19-Nov 7:00 AM ET)
Globe Newswire (Mon, 17-Nov 10:15 AM ET)
SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Globe Newswire (Wed, 5-Nov 4:20 PM ET)
SCYNEXIS Secures $22 Million from GSK Agreement—Cash Runway Now Extended Over Two Years
Market Chameleon (Wed, 15-Oct 7:20 AM ET)
SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study
Globe Newswire (Wed, 15-Oct 8:00 AM ET)
Globe Newswire (Tue, 30-Sep 8:00 AM ET)
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
Scynexis trades on the NASDAQ stock market under the symbol SCYX.
As of December 22, 2025, SCYX stock price declined to $0.61 with 235,404 million shares trading.
SCYX has a beta of 1.04, meaning it tends to be more sensitive to market movements. SCYX has a correlation of 0.05 to the broad based SPY ETF.
SCYX has a market cap of $25.68 million. This is considered a Sub-Micro Cap stock.
Last quarter Scynexis reported $334,000 in Revenue and -$.17 earnings per share. This beat revenue expectation by $186,330 and exceeded earnings estimates by $.03.
In the last 3 years, SCYX traded as high as $3.87 and as low as $.57.
The top ETF exchange traded funds that SCYX belongs to (by Net Assets): VTI, VXF, BSVO.
SCYX has underperformed the market in the last year with a price return of -39.4% while the SPY ETF gained +18.8%. SCYX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -45.3% and -6.6%, respectively, while the SPY returned +3.5% and +0.2%, respectively.
SCYX support price is $.60 and resistance is $.65 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SCYX shares will trade within this expected range on the day.
